



RISK-SHARING PROGRAM

At its heart, the drug development process is an exercise of risk management. Consistently with its mission, BSP is alongside its customers in supporting the innovation in new treatments against cancer and also in other therapeutic areas that improve the quality of life of patients.

For this purpose, BSP has decided to promote a "RISK SHARING" initiative aimed to reduce the cost of Pre-Clinical and Phase 1 Clinical programs, which are the phases with higher risk of failure.

Such program shall be applied to any projects in Preclinical and Clinical Phase 1 transferred to BSP starting from October 2019. The term of the program shall be two years, unless extended by the company.

The incentive shall be applied to the value added by BSP to:

- the development and delivery of formulated GLP products to feed in vitro and animal experiments in the pre-clinical study activities; and
- the manufacture of products out of the cGMP facilities for the phase 1 clinical products supplied for human use.

Upon the official awarding of the project, the Risk-Sharing Program shall include:

- a deduction on the prices quoted by BSP for the development activities, technology transfer, GLP and GMP productions; and
- a reduction of the percentage applied as handling fees for the services related to the procurement of materials and for the equipment usage.

The Risk-Sharing Program shall continue for the awarded projects until completion of the Clinical Phase 1 and before the commencement of Phase 2. Details on the model application shall be provided through direct inquires.

For further details, please write to:

Business_Dev@Bsppharmaceuticals.com